Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

Inclusion Criteria:

• Are being evaluated for the diagnosis and/or treatment of Acute Myelogenous Leukemiaor High Grade myelodysplastic syndrome (defined as greater than 10 percent blasts onexamination of the bone marrow aspirate).

• Have not undergone prior cytotoxic therapy for acute myelogenous leukemia or HighGrade myelodysplastic syndrome in the past 3 months other than hydroxyurea orRevlimid.

• Have not previously received an allogeneic peripheral blood or bone marrow stem celltransplant for their disease.

• Are able to sign an informed consent. Informed consent must be signed at the time ofenrollment and prior to the collection of any specimens and/or clinical data (otherthan PHI needed to screen and identify patients, which will be promptly discarded ina secure fashion if patient is not enrolled on study)

• Are at least 18 years of age.

• Do not have any serious medical or psychiatric illness, other than that treated bythis study which would limit the ability of the patient to receive therapy or giveinformed consent.

• Have been informed of the investigational nature of this study and given writteninformed consent in accordance with institutional and federal guidelines.

Exclusion Criteria:

• Subjects who are less than 18 years of age.

• Subjects with limited decision making capacity.

• Subjects who have received prior cytotoxic therapy, other than hydroxyurea orRevlimid, for their disease within the past three months.

• Patients with a diagnosis of chronic myelogenous leukemia in blast crisis, AcutePromyelocytic Leukemia, or Bi-lineage leukemia.

• Subjects who have previously undergone an allogeneic peripheral blood stem celltransplant.

• Have an active malignancy other than acute myelogenous leukemia (AML) ormyelodysplastic syndrome (MDS) at the time of evaluation or a prior history oftreatment for a malignancy other than AML or MDS within the past 2 years.